A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Atish D ChoudhuryKathryn P GrayJeffrey G SupkoLauren C HarshmanMary-Ellen TaplinAmanda F PaceMatthew FarinaKatherine A ZukotynskiBrandon BernardPhilip W KantoffMark PomerantzChristopher Sweeney

Published in: The Prostate (2018)

Based on tolerability and preliminary efficacy, 40 mg cabozantinib plus 1000 mg abiraterone daily is the RP2D.

Keyphrases

clinical trial
open label
metastatic renal cell carcinoma
double blind
squamous cell carcinoma
small cell lung cancer
phase ii
physical activity
phase iii